PMC9885096_01
Immunotherapy schedules in this study. (A) Anti-CD19/anti-CD22 CAR T cell cocktail treatment schedule. (B) Anti-CD19 CAR T cell treatment schedule. (C) Blinatumomab treatment schedule.
fped-10-1100404-g001.jpg
PMC9885096_01_fped-10-1100404-g001.jpg
F1
T-cell therapy was infused with a single dose of autologous anti-CD19 CAR T cells on day 0. The details are shown in Figure 1.
Swimmer plot of patients' treatment and outcome.
fped-10-1100404-g002.jpg
PMC9885096_01_fped-10-1100404-g002.jpg
F2
Figure 2 depicts the swimmer plot of patients' treatment and outcome.
Droplet digital polymerase chain reaction analysis of CAR T cells expansion and persistence in vivo. (A) Expansion and persistence of anti-CD22 CAR T cells in peripheral blood of case 1. (B) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 1. (C) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 2. (D) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 7.
fped-10-1100404-g003.jpg
PMC9885096_03_fped-10-1100404-g003.jpg
F3
T cells with 0.6 x 106/kg. The expansion of anti-CD19 CAR T cells in the peripheral blood is shown in Figure 3D.
PMC9885096_02
PMC9885096_03
Droplet digital polymerase chain reaction analysis of CAR T cells expansion and persistence in vivo. (A) Expansion and persistence of anti-CD22 CAR T cells in peripheral blood of case 1. (B) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 1. (C) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 2. (D) Expansion and persistence of anti-CD19 CAR T cells in peripheral blood of case 7.
fped-10-1100404-g003.jpg
PMC9885096_03_fped-10-1100404-g003.jpg
F3
T cells with 0.6 x 106/kg. The expansion of anti-CD19 CAR T cells in the peripheral blood is shown in Figure 3D.